Arrowhead Research | ARWR - Sales Revenues


Arrowhead Research reported $264.03M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 678M 342M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025